Clinical Trials
195 trialsNCT04984733 2026-05-18
ELEVATE
University of Southampton
Phase 2 Completed
NCT02308527 2026-05-12
BEACON
University of Birmingham
Phase 2 Completed
NCT03519412 2026-03-03
ARETHUSA
IFOM ETS - The AIRC Institute of Molecular Oncology
Phase 2 Completed
NCT03746080 2025-11-14
Whole Brain Radiation Therapy With Standard Temozolomide Chemo-Radiotherapy and Plerixafor in Treating Patients With Glioblastoma
Stanford University
Phase 2 Completed
NCT01991977 2025-10-20
18F-DOPA-PET in Finding Tumors in Patients With Newly Diagnosed Gliomas Undergoing Radiation Therapy
Mayo Clinic
Phase 2 Completed
NCT04388475 2025-08-12
Open-label Study Investigating of OKN-007 Combined With Temozolomide in Patients With Recurrent Glioblastoma
Oblato, Inc.
Phase 2 Completed
NCT03137888 2025-08-03
Spectroscopic MRI-Guided Radiation Therapy Planning in Glioblastoma
Emory University
Phase 2 Completed
NCT03778294 2025-07-03
18F-DOPA-PET/MRI Scan in Imaging Elderly Patients With Newly Diagnosed Grade IV Malignant Glioma or Glioblastoma During Planning for a Short Course of Proton Beam Radiation Therapy
Mayo Clinic
Phase 2 Completed
NCT02781792 2025-06-27
Temozolomide Chronotherapy for High Grade Glioma
Washington University School of Medicine
Phase 2 Completed
NCT01009788 2025-03-14
ABT-888 and Temozolomide for Metastatic Breast Cancer and BRCA1/2 Breast Cancer
Massachusetts General Hospital
Phase 2 Completed
NCT03495960 2025-01-30
FIORELLA
International Extranodal Lymphoma Study Group (IELSG)
Phase 2 Completed
NCT04280848 2025-01-09
UCPVax-Glio
Centre Hospitalier Universitaire de Besancon
Phase 2 Completed
NCT01149850 2024-09-19
Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma
Jonsson Comprehensive Cancer Center
Phase 2 Completed
NCT00114140 2024-07-08
Temozolomide and Radiation Therapy in Treating Patients With Gliomas
Radiation Therapy Oncology Group
Phase 2 Completed
NCT01119508 2024-06-06
Ipilimumab + Temozolomide in Metastatic Melanoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03139916 2024-05-16
Bavituximab With Radiation and Temozolomide for Patients With Newly Diagnosed Glioblastoma
Massachusetts General Hospital
Phase 2 Completed
NCT00589875 2024-04-03
BrTK02
Candel Therapeutics, Inc.
Phase 2 Completed
NCT01525082 2024-02-06
Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors
Stanford University
Phase 2 Completed
NCT01827384 2023-09-29
MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations
National Cancer Institute (NCI)
Phase 2 Completed
NCT04166435 2023-09-06
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer
Yale University
Phase 2 Completed
NCT00846430 2023-08-30
Medical Treatment of "High-Risk" Neurofibromas
Corewell Health West
Phase 2 Completed
NCT00591370 2023-07-25
Phase II Trial of Extended-Dosing Temozolomide in Patients With Melanoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT02330991 2023-07-24
A Trial of One-week on/One-week Off Temozolomide Versus Continuous Dose-Intense Temozolomide in Patients With Glioblastoma Multiforme at First Relapse
Beijing Sanbo Brain Hospital
Phase 2 Completed
NCT01466686 2023-07-03
Low Dose Radiation Therapy for Glioblastoma Multiforme
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT00080938 2023-06-29
Temozolomide and Radiation Therapy in Treating Patients With Brain Metastasis Secondary to Non-Small Cell Lung Cancer
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT02366728 2023-06-08
ELEVATE
Duke University
Phase 2 Completed
NCT05858177 2023-05-15
MPPGL
Peking Union Medical College Hospital
Phase 2 Completed
NCT00582075 2023-03-27
RAD0102
University of Alabama at Birmingham
Phase 2 Completed
NCT00100802 2023-02-15
Radiation Therapy, Temozolomide, and Lomustine in Treating Young Patients With Newly Diagnosed Gliomas
Children's Oncology Group
Phase 2 Completed
NCT02511132 2022-12-22
A Two-part Phase IIb Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Ewing's Sarcoma
Gradalis, Inc.
Phase 2 Completed
NCT03079440 2022-12-06
TEMCAP in Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors
Asan Medical Center
Phase 2 Completed
NCT01767194 2022-10-24
Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT02727387 2022-09-19
EW-2
Italian Sarcoma Group
Phase 2 Completed
NCT01835145 2022-08-04
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT01062425 2022-07-26
Temozolomide and Radiation Therapy With or Without Cediranib Maleate in Treating Patients With Newly Diagnosed Glioblastoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT02358356 2022-07-05
CONTROL NETS
Australasian Gastro-Intestinal Trials Group
Phase 2 Completed
NCT00602576 2022-06-14
Temozolomide and Sorafenib in Treating Patients With Metastatic or Unresectable Melanoma
Abramson Cancer Center at Penn Medicine
Phase 2 Completed
NCT01004874 2022-04-13
Avastin/Radiation (XRT)/Temozolomide (Temodar) Followed by Avastin/Temodar/Topotecan for Glioblastoma
Duke University
Phase 2 Completed
NCT03832621 2022-04-04
MAYA
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Completed
NCT00275002 2022-02-11
O6-Benzylguanine and Temozolomide in Treating Young Patients With Recurrent or Progressive Gliomas or Brain Stem Tumors
National Cancer Institute (NCI)
Phase 2 Completed
NCT00805961 2021-12-08
RT, Temozolomide, and Bevacizumab Followed by Bevacizumab/Everolimus in First-line Treatment of GBM
SCRI Development Innovations, LLC
Phase 2 Completed
NCT01506609 2021-10-25
Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide (TMZ) or In Combination With Carboplatin and Paclitaxel Versus Placebo in Participants With Breast Cancer Gene (BRCA)1 and BRCA2 Mutation and Metastatic Breast Cancer
AbbVie
Phase 2 Completed
NCT00112502 2021-10-18
Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03034135 2021-09-13
Safety, Tolerability and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma
Cantex Pharmaceuticals
Phase 2 Completed
NCT00049361 2021-09-09
Radiation Therapy Plus Thalidomide and Temozolomide in Treating Patients With Newly Diagnosed Brain Metastases
Wake Forest University Health Sciences
Phase 2 Completed
NCT02414009 2021-09-09
CAPTEM
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Completed
NCT02596828 2021-08-05
Prospective Pilot Trial to Assess a Multimodal Molecular Targeted Therapy in Children, Adolescent and Young Adults With Relapsed or Refractory High-grade Pineoblastoma
University of Regensburg
Phase 2 Completed
NCT01217437 2021-07-23
Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors
National Cancer Institute (NCI)
Phase 2 Completed
NCT00528437 2021-07-08
Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue Followed by 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors
NYU Langone Health
Phase 2 Completed
NCT02805179 2021-04-15
A Study of High-Dose Chemoradiation Using Biologically-Based Target Volume Definition in Patients With Glioblastoma
University of Michigan Rogel Cancer Center
Phase 2 Completed